The Active Pharmaceutical Ingredients Manufacturing facility at Mahad of Kopran Research Laboratories Limited a 100 percent subsidiary of Kopran Limited was inspected by the USFDA in January 2019 without any observation under Para 483. This was notified to the Stock Exchange on 25th January 2019. The Company had filed the DMF of Atenolol which has now been approved by the USFDA and the Company can commence supplies of the API Atenolol to the US market.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
